title: Normal and atypical butyrylcholinesterases in placental development, function, and malfunction.
abstract: 1. In utero exposure to poisons and drugs (e.g., anticholinesterases, cocaine) is frequently associated with spontaneous absorption and placental malfunction. The major protein interacting with these compounds is butyrylcholinesterase (BuChE), which attenuates the effects of such xenobiotics by their hydrolysis or sequestration. Therefore, we studied BuChE expression during placental development. 2. RT-PCR revealed both BuChEmRNA and acetylcholinesterase (AChE) mRNA throughout gestation. However, cytochemical staining detected primarily BuChE activity in first-trimester placenta but AChE activity in term placenta. 3. As the atypical variant of BuChE has a narrower specificity for substrates and inhibitors than the normal enzyme, we investigated its interactions with alpha-solanine and cocaine, and sought a correlation between the occurrence of this variant and placental malfunction. 4. Atypical BuChE of serum or recombinant origin presented > 10-fold weaker affinities than normal BuChE for cocaine and alpha-solanine. However, BuChE in the serum of the heterozygote and a homozygous normal were similar in their drug affinities. Therefore, heterozygous serum or placenta can protect the fetus from drug or poison exposure, unlike homozygous atypical serum or placenta. 5. Genotype analyses revealed that heterozygous carriers of atypical BuChE were threefold less frequent among 49 patients with placental malfunction than among 76 controls of the entire Israeli population. These observations exclude heterozygote carriers of atypical BuChE from being at high risk for placental malfunction under exposure to anticholinesterases.
authors.affiliation: Department of Biological Chemistry, Hebrew University of Jerusalem, Israel.
authors.forename: M
authors.initials: M
authors.lastname: Sternfeld
authors.forename: J
authors.initials: J
authors.lastname: Rachmilewitz
authors.forename: Y
authors.initials: Y
authors.lastname: Loewenstein-Lichtenstein
authors.forename: C
authors.initials: C
authors.lastname: Andres
authors.forename: R
authors.initials: R
authors.lastname: Timberg
authors.forename: S
authors.initials: S
authors.lastname: Ben-Ari
authors.forename: C
authors.initials: C
authors.lastname: Glick
authors.forename: H
authors.initials: H
authors.lastname: Soreq
authors.forename: H
authors.initials: H
authors.lastname: Zakut
mesh_terms: D000110:Acetylcholinesterase / Q000187:drug effects / Q000235:genetics; D000483:Alleles; D002091:Butyrylcholinesterase / Q000097:blood / Q000235:genetics* / Q000502:physiology; D002800:Cholinesterase Inhibitors / Q000494:pharmacology; D002802:Cholinesterases / Q000097:blood / Q000187:drug effects / Q000235:genetics; D003042:Cocaine / Q000494:pharmacology; D004797:Enzyme-Linked Immunosorbent Assay; D005006:Ethnicity; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006651:Histocytochemistry; D006801:Humans; D010920:Placenta / Q000201:enzymology* / Q000502:physiology*; D010929:Placentation; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D012333:RNA, Messenger / Q000032:analysis / Q000378:metabolism; D011994:Recombinant Proteins / Q000097:blood / Q000187:drug effects / Q000235:genetics; D012992:Solanine / Q000494:pharmacology; D014327:Trophoblasts / Q000201:enzymology
chemical_list: D002800:Cholinesterase Inhibitors; D012333:RNA, Messenger; D011994:Recombinant Proteins; D012992:Solanine; D000110:Acetylcholinesterase; D002091:Butyrylcholinesterase; D002802:Cholinesterases; D003042:Cocaine